Browsing Bergen Open Research Archive by Author "Gjerde, Jennifer"
Now showing items 1-5 of 5
-
The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
Helland, Thomas; Gjerde, Jennifer; Dankel, Simon N; Fenne, Ingvild Sveinsgjerd; Skartveit, Linn; Drangevåg, Andreas; Bozickovic, Olivera; Flågeng, Marianne Hauglid; Søiland, Håvard; Mellgren, Gunnar; Lien, Ernst Asbjørn (Peer reviewed; Journal article, 2015-04-13)Introduction: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sumof tamoxifen and all itsmetabolites. 4-Hydroxytamoxifen ... -
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Gjerde, Jennifer; Geisler, Jürgen; Lundgren, Steinar; Ekse, Dagfinn; Varhaug, Jan Erik; Mellgren, Gunnar; Steen, Vidar Martin; Lien, Ernst Asbjørn (Peer reviewed; Journal article, 2010-06-21)Background The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and ... -
Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults
Bjørndal, Bodil; Strand, Elin; Gjerde, Jennifer; Bohov, Pavol; Svardal, Asbjørn; Diehl, Bernd W. K.; Innis, Sheila M.; Berger, Alvin; Berge, Rolf Kristian (Peer reviewed; Journal article, 2014-05-17)Background: Herring roe is an underutilized source of n-3 polyunsaturated fatty acids (PUFAs) for human consumption with high phospholipid (PL) content. Studies have shown that PL may improve bioavailability of n-3 PUFAs. ... -
A randomized phase II pre-surgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor positive breast cancer
Serrano, Davide; Lazzeroni, Matteo; Gandini, Sara; Macis, Debora; Johansson, Harriet; Gjerde, Jennifer; Lien, Ernst Asbjørn; Feroce, Irene; Pruneri, Giancarlo; Sandri, Maria Teresa; Bassi, Fabio; Brenelli, Fabricio; Luini, Alberto; Cazzaniga, Massimiliano; Varricchio, Clara; Guerrieri-Gonzaga, Aliana; DeCensi, Andrea; Bonanni, Bernardo (Peer reviewed; Journal article, 2013-06-20)Introduction: We previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long ... -
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
Moi, Line Leonora Haugan; Flågeng, Marianne Hauglid; Gjerde, Jennifer; Madsen, Andre; Røst, Therese Halvorsen; Gudbrandsen, Oddrun Anita; Lien, Ernst Asbjørn; Mellgren, Gunnar (Peer reviewed; Journal article, 2012-06-15)Background: Steroid receptor coactivators (SRCs) may modulate estrogen receptor (ER) activity and the response to endocrine treatment in breast cancer, in part through interaction with growth factor receptor signaling ...